• EE79 Cost-Utility Analyses of Glofitamab for the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy in Italy

    Dec 1, 2023, 00:00

  • EE559 The Burden of Disease of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration in Honduras, El Salvador, Dominican Republic

    Dec 1, 2023, 00:00

  • MT13 Digging into the Medical Technology HTA Process in Tunisia

    Dec 1, 2023, 00:00

  • HTA327 Acceptance of Real-World Evidence As Comparative Efficacy in Lieu of Trial Eviden A Review of Past NICE Appraisals in Oncology

    Dec 1, 2023, 00:00

  • HTA322 Modelling Antifibrotic Therapies for Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease: Learnings from NICE Submissions from the Past Decade

    Dec 1, 2023, 00:00

  • PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

    Dec 1, 2023, 00:00

  • EPH191 Iron Deficiency Anemia Is Associated with Colorectal and Stomach Cancer Diagnoses in Germany

    Dec 1, 2023, 00:00

  • RWD39 Comparative Effectiveness and Health Resource Utilization of Xuesaitong Soft Capsule in Patients with Stroke of Secondary Prevention in China: A Retrospective Cohort Study

    Dec 1, 2023, 00:00

  • HPR65 Pricing and Reimbursement Mechanisms for Advanced Therapeutic Medicinal Products in 20 Countries

    Dec 1, 2023, 00:00

  • PCR7 People Living With HIV’s Lived Experiences of Long-Acting Injectable Antiretroviral Treatment Administrations in France Show the Central Role of Hospital Nurses in Care: A Qualitative Study (PANTER)

    Dec 1, 2023, 00:00

  • EE693 Assessing the Impact of Additional Follow-up From the CheckMate-274 Trial on the Cost-Effectiveness (CE) Profile of Nivolumab Versus Surveillance in High-Risk, Muscle-Invasive Urothelial Carcinoma (MIUC)

    Dec 1, 2023, 00:00

  • HTA346 The Use of Real-World Evidence in Health Technology Assessment Decisions in Sweden and the UK: A Natural Language Processing (NLP) Approach

    Dec 1, 2023, 00:00

  • EPH122 Global Burden of Disease Study on Chikungunya: Estimating Dalys and Cost Burden

    Dec 1, 2023, 00:00

  • EPH78 A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs

    Dec 1, 2023, 00:00

  • EPH149 Prevalence, Burden of Disease, and Treatment Patterns of Vitiligo in Patients Across European Countries

    Dec 1, 2023, 00:00

  • PCR275 An Interpretive Phenomenological Analysis of Financial Toxicity in Indonesian Cancer Patients

    Dec 1, 2023, 00:00

  • PCR225 The Added Value of the Cognition, Dining, Gastrointestinal Problems, Sleep, and Tiredness Bolt-Ons for the EQ-5D-5L in Patients With Coeliac Disease

    Dec 1, 2023, 00:00

  • HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany

    Dec 1, 2023, 00:00

  • CO158 Analysis of Clinical Endpoints in Clinical Trials for NAFL and NASH: A Comprehensive Review

    Dec 1, 2023, 00:00

  • CO171 Associations of Sex and Race with Relative Efficacy in Clinical Trials

    Dec 1, 2023, 00:00

  • EE546 Development of a Drug Price Index for Approved Cystic Fibrosis Treatments

    Dec 1, 2023, 00:00

  • MSR20 Estimating Undetected Medication Errors at Care Transitions: A Framework to Support Decision-Making

    Dec 1, 2023, 00:00

  • RWD161 Identifying and Characterizing Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Population in Finland

    Dec 1, 2023, 00:00

  • HPR185 The Influence of Value Frameworks on Payer and Oncologist Decision-Making in the United States (US)

    Dec 1, 2023, 00:00

  • EE354 Value for Money: Evaluating the Economic Benefit of a Hypothetical Disease Modifying Therapy for Alzheimer's Disease From Canadian Payer and Societal Perspectives

    Dec 1, 2023, 00:00

  • PCR36 Building a COA Strategy in Allergic Fungal Rhinosinusitis: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • EPH10 ICD-10 Surrogates of the Modified Frailty Index Predict Hospital Referrals in Outpatients Followed in German General Practices

    Dec 1, 2023, 00:00

  • HPR60 Voluntary Scheme for Branded Medicines Pricing and Access vs Statutory Scheme: A Case of Six vs Half a Dozen?

    Dec 1, 2023, 00:00

  • CO186 Characteristics of Psoriasis Patients According to Their Level of Severity Based on a Real-World Ambulatory Medical Database in Fran Preliminary Results

    Dec 1, 2023, 00:00

  • EPH215 Informal Caregiving and Illicit Drug Use in England and Wales

    Dec 1, 2023, 00:00

  • HTA21 A Retrospective Review of Recent NICE Technology Appraisals From 2021 to 2023 to Investigate the Consideration and Acceptability of Cure Modelling Assumptions

    Dec 1, 2023, 00:00

  • CO147 Impact of COVID-19 on Patients With Asthma in US Routine Care

    Dec 1, 2023, 00:00

  • EE565 Healthcare Consumption and Costs of Hemophilia B in France

    Dec 1, 2023, 00:00

  • Health Service Delivery Process of Care

    Dec 1, 2023, 00:00

  • PCR106 Merging Adolescent and Adult Preference Data Into a Potential Latent Scale EQ-5D-Y-3L Value Set: A Latent Class Approach to Analyze Contribution of Each Group to the Preference Weights

    Dec 1, 2023, 00:00

  • HTA99 Expert Validation on Proposed Framework for Differentiated HTA Criteria for Rare Disease Drugs in Brazil

    Dec 1, 2023, 00:00

  • EPH16 Exploring the Effects of the COVID-19 Pandemic on Pneumococcal Disease in Fran A Comprehensive Analysis of Public Health Impact and Economic Burden

    Dec 1, 2023, 00:00

  • HSD68 Emotions of Physicians Elicited by Their Patients’ Rare Disease Diagnoses: A Cross-Sectional Study in Europe and the United States

    Dec 1, 2023, 00:00

  • EE185 Economic Burden of Chlamydia Trachomatis: A Targeted Literature Review and Gap Analysis

    Dec 1, 2023, 00:00

  • EPH221 Age, Sex, and Comorbidity Differences Between Patients with Mild and Severe Aortic Stenosis in German Cardiology Practices

    Dec 1, 2023, 00:00

  • EE645 How Wrong Can It Be? The Impact of Using Inappropriate Adult-Specific Value Set for EQ-5D-Y in Cost-Effectiveness Estimates

    Dec 1, 2023, 00:00

  • EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France

    Dec 1, 2023, 00:00

  • EPH22 Mean Time on Triptan Treatment Among Danish Migraine Patients Before Discontinuing Treatment—A Register-Based Study

    Dec 1, 2023, 00:00

  • EE284 A Qualitative Primary Market Research Study on the Economic Investment of Scaling up Bariatric Surgery Capacity Within the NHS

    Dec 1, 2023, 00:00

  • PT19 Analysis of the Access to Medicines for Rare Diseases in Countries from the Balkan Peninsula: A Comparative Analysis

    Dec 1, 2023, 00:00

  • PT6 What Do Patients Value? Development of a Preference-Based Health Utility Score for Chronic Obstructive Pulmonary Disease (COPD)

    Dec 1, 2023, 00:00

  • Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis

    Dec 1, 2023, 00:00

  • Care Pathway Analysis to Inform the Earliest Stages of Technology Development: Scoping Oncological Indications in Need of Innovation

    Dec 1, 2023, 00:00

  • PCR74 Patient-Centricity in Haemato-Oncology and Oncology Clinical Trials – A Systematic Literature Review on FDA-Approved Treatments From January 2020 to June 2023

    Dec 1, 2023, 00:00

  • RWD10 Real-World Safety and Effectiveness of Sodium Oxybate in the Management of Narcolepsy: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE243 Utilization of Healthcare Resources and Costs of Hemolytic Disease of Fetus and Newborn (HDFN) in Israel

    Dec 1, 2023, 00:00

  • HPR54 Policy Approaches to the Regulation and Reimbursement of Pediatric Medicines: Comparing Canadian, European, and UK Health Systems

    Dec 1, 2023, 00:00

  • EE456 Cost-Effectiveness of the Development Assistance for Health in Sub-Saharan Africa for HIV, Malaria and Tuberculosis (1995-2018)

    Dec 1, 2023, 00:00

  • PCR10 A Comparative Study of Health-Related Quality-of-Life Outcomes in Patients Undergoing Total Hip Arthroplasty in the Hungarian Public and Private Healthcare

    Dec 1, 2023, 00:00

  • MT71 Modelling the Value of Integrating Digital Cellular Pathology in the United Kingdom

    Dec 1, 2023, 00:00

  • CO117 Prognostic Factors and Surrogate Endpoints in Obstructive Hypertrophic Cardiomyopathy: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE760 Using Discrete Choice Experiment to Elicit Treatment Preferences for Acute Allergic Reactions in Sweden: The Case of Patients with Swallowing Problems

    Dec 1, 2023, 00:00

  • CO154 Evaluating Patients Perception of Generic Medicines in Greece

    Dec 1, 2023, 00:00

  • RWD102 The Real-World Effectiveness of Tixagevimab and Cilgavimab in Immunocompromised Patients: A Single Center Study in Taiwan

    Dec 1, 2023, 00:00

  • EE92 Introduction to the Duchenne Muscular Dystrophy Burden-of-Illness Study Expanded (US AND SPAIN)

    Dec 1, 2023, 00:00

  • MT64 The Role of Digital Health Technologies in Out-of-Hospital Management of Mental Health Disorders in the UK

    Dec 1, 2023, 00:00

  • HPR99 Regional Access Timelines in Italy: Factors Affecting Speed and Equity

    Dec 1, 2023, 00:00

  • EE732 Cost-Effectiveness Analysis of Strategies of Autologous Stem-Cell Transplantation and Maintenance Therapy for Transplant-Eligible Multiple Myeloma in China

    Dec 1, 2023, 00:00

  • EE728 Examining Hospital-Onset Urinary Tract Infection (HO-UTI) in Male Patients – Modeling the Economic Impact of Utilizing External Male Wicking Catheters (EMWCS)

    Dec 1, 2023, 00:00

  • EE70 Real-World Comparison of Healthcare Resource Utilization and Costs Between Patients with Chronic Lymphocytic Leukemia Treated with First-Line Ibrutinib or Acalabrutinib

    Dec 1, 2023, 00:00

  • EE142 Healthcare Resource Use and Costs Associated with Herpes Zoster/Post-Herpetic Neuralgia Episodes in Italy: A Retrospective Observational Study

    Dec 1, 2023, 00:00

  • HTA199 Digital Health Application (DiGA) vs Other Digital Health Technologies (DHT) as Part of Disease Management Programs (DMP)—Assessment Requirements in Germany Diverge Between HTA Authorities

    Dec 1, 2023, 00:00

  • CO190 Cannabis-Based Formulations: Clinical and Economic Results Promising Savings and Sustainability

    Dec 1, 2023, 00:00

  • EE250 Economic Evaluation and Budget Impact of ERTs in Patients with Pompe Disease – a Systematic Literature Review

    Dec 1, 2023, 00:00

  • HSD102 Preferences of Nurses for Attributes of Pediatric Hexavalent Vaccines in the United Kingdom

    Dec 1, 2023, 00:00

  • CO148 Effectiveness of Tocilizumab in Refractory Graves' Orbitopathy in a Real-World Setting

    Dec 1, 2023, 00:00

  • RWD139 Exploring Respiratory Syncytial Virus and Influenza Trends Pre- and Post-COVID-19 in the US and EU-5 Countries

    Dec 1, 2023, 00:00

  • EE346 Evaluating the Economic Burden of Osteoporosis in the United States: Insights from a MEPS-Based Analysis

    Dec 1, 2023, 00:00

  • HTA24 Are the Hurdles Too High for Access to Gene Therapies in the UK?

    Dec 1, 2023, 00:00

  • CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia

    Dec 1, 2023, 00:00

  • RWD101 Intravitreal Therapies and Their Patterns of Use in Lombardy Region

    Dec 1, 2023, 00:00

  • EE27 Risk, Use, and Cost of Infection-Related Hospitalization of Individuals With Alzheimer’s Disease or Dementia

    Dec 1, 2023, 00:00

  • PCR59 Self-Reported Health Status and Its Predictors Among People with Diabetes in France

    Dec 1, 2023, 00:00

  • EE751 Economic Evaluation of Hepatitis B Vaccination Programme in Finland

    Dec 1, 2023, 00:00

  • RWD80 Labor Impact in Patients with Rheumatoid Arthritis (RA) Treated with Advanced Therapies

    Dec 1, 2023, 00:00

  • PCR244 Core Oncology Outcome Strategies: Do They Offer an Opportunity for Simplicity and Consistency, or Pose a Risk to Comprehensive Understanding of Patient Experiences?

    Dec 1, 2023, 00:00

  • EE298 Process and Results of the Third Update of the Dutch Guideline for Economic Evaluations in Healthcare: Evolution Instead of Revolution

    Dec 1, 2023, 00:00

  • EE277 Assessing the Cost-Effectiveness of Semaglutide 2.4 Mg Injection for Chronic Weight Management in Portugal

    Dec 1, 2023, 00:00

  • HPR201 Lessons from the COVID-19 Vaccines Taskforce

    Dec 1, 2023, 00:00

  • EE666 Cost-Effectiveness of Duvelisib Versus the Bendamustine Plus Rituximab Regimen for Relapsed/Refractory Follicular Lymphoma Patients in China

    Dec 1, 2023, 00:00

  • EE226 Economic Evaluation of Trastuzumab in HER2-Positive Early Breast Cancer in Indonesia: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • HPR90 Global Disparities in P4P Programs for Diabetes Care: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • EPH59 An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy

    Dec 1, 2023, 00:00

  • RWD140 Quality of Electronic Health Records: Encountering Misclassification

    Dec 1, 2023, 00:00

  • PCR154 How and Why Do Multimorbid Patients Adhere to Their Medications? A Qualitative Study Looking Beyond the Risk-Benefit Scale

    Dec 1, 2023, 00:00

  • HSD122 A Systematic Review on Equal Access to Treatment for Hearing Loss in Chile: Do All People Have the Same Opportunities to Receive Appropriate Treatment?

    Dec 1, 2023, 00:00

  • EE40 Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

    Dec 1, 2023, 00:00

  • EE297 Healthcare Resources Utilization Among Sectors in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE560 A Comparison of Time-Driven Activity-Based Costs for Patients and Caregivers Receiving Intravitreal Treatments for Neovascular Age-Related Macular Degeneration

    Dec 1, 2023, 00:00

  • PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach

    Dec 1, 2023, 00:00

  • EPH263 Algorithmic Public Health? The Path Towards AI-Assisted Health Promotion

    Dec 1, 2023, 00:00

  • EE621 Cost-Effectiveness Analysis of iGlarLixi Compared With Basal Bolus Insulin Regimen in Triple Metabolic Goal in Type 2 Diabetes Mellitus in Latin America

    Dec 1, 2023, 00:00

  • PT40 Epidemiology and Burden of Illness of Lupus in Children by Form of Lupus: A Retrospective Longitudinal National Hospital Claims Study in France

    Dec 1, 2023, 00:00

  • HSD43 Survey Research Using PRO Data in Clinical Practi Lessons Learnt from the Nordic Countries

    Dec 1, 2023, 00:00

  • HPR35 Modelling the Effects of Smoking on Healthy Life Expectancy (HLE) in England

    Dec 1, 2023, 00:00

  • RWD163 The Economic Burden of Cutaneous Malignant Melanoma in Gree Analysis of Real-Word Health Insurance Data

    Dec 1, 2023, 00:00

  • MSR86 Use of Data Linkage for the Evaluation of Medical Devices: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HTA106 What Are the Main Drivers for Decision-Making Regarding the Incorporation of a Healthcare Technology By CONITEC in Brazil? A Study in the Cardiovascular, Oncology, and Respiratory Fields

    Dec 1, 2023, 00:00

  • HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

    Dec 1, 2023, 00:00

  • PCR258 Baseline Demographic and Clinical Characteristics of Patients with Plaque Psoriasis Treated with Brodalumab in the Canadian Real-World Setting: Results from the Care Study

    Dec 1, 2023, 00:00

  • CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives

    Dec 1, 2023, 00:00

  • EE680 Axicabtagene Ciloleucel as Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • HTA359 Market Access of ATMPs in Fran Challenges and Opportunities

    Dec 1, 2023, 00:00

  • HTA211 Requirements for Economic Evaluations for Health Technology Assessment Submissions across Different Countries

    Dec 1, 2023, 00:00

  • SA67 Considerations for Including Different Routes of Administration in Network Meta-Analysis: A Comprehensive Review

    Dec 1, 2023, 00:00

  • EE636 Cost-Minimization Analysis of Delafloxacin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Jordan

    Dec 1, 2023, 00:00

  • HSD99 Analysis of Evidence Information About Herbal Medicinal Products and Its Use for Postgraduate Pharmacy Trainings in Ukraine

    Dec 1, 2023, 00:00

  • HTA65 Economic Evaluation of Medical Devices By the French National Authority (2014-2022): Where Do We Stand?

    Dec 1, 2023, 00:00

  • CO138 Outcomes and Health-Related Costs of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Public Health System

    Dec 1, 2023, 00:00

  • CO24 Daratumumab in Combination with Lenalidomide and Dexamethasone Improves Survival in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: A Parametric Network Meta-Analysis in a United Kingdom Setting

    Dec 1, 2023, 00:00

  • HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in Fran A National Study Based on the Comprehensive Inpatient Stays Database

    Dec 1, 2023, 00:00

  • PCR78 Establishing Meaningful Change Thresholds for EORTC QLQ-CLL17 Domain Scores: An Analysis Based on the TRANSCEND CLL 004 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Dec 1, 2023, 00:00

  • HTA127 No Half Measures: Health Inequalities in Technology Appraisal

    Dec 1, 2023, 00:00

  • EPH28 Burden of Chronic Lymphocytic Leukemia in the United States: A Review of Literature

    Dec 1, 2023, 00:00

  • CO32 Validation of a Scoring Algorithm for the Clinician-Reported Outcome ”Prurigo Activity and Severity (PAS)’’ Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis

    Dec 1, 2023, 00:00

  • HTA7 Exploring the Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab across Six Oncology Indications

    Dec 1, 2023, 00:00

  • EPH62 Impact of Ethnicities on the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes: Results of a Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • HTA139 Uptake of Early Heath Technology Assessment in the United Kingdom: A Literature Review of Empirical Studies

    Dec 1, 2023, 00:00

  • Using Artificial Intelligence to Enhance Efficiency in Systematic Reviews and Meta-Analyses

    Dec 1, 2023, 00:00

  • EE236 The Economic Impact of Third Line Chronic Phase Chronic Myeloid Leukemia Treatment in Greece From a National Payer Perspective

    Dec 1, 2023, 00:00

  • HTA167 Another Hurdle in Anticancer New Drug Listing in Korea—Setting the Reimbursement Scope

    Dec 1, 2023, 00:00

  • MT9 The Role of HTA Agencies in Relation to Medical Technologies: A Discourse Analysis

    Dec 1, 2023, 00:00

  • PCR158 The Uniqueness and Overlap of the EQ-HWB and the EQ-5D-5L in Four Diseases, Healthy Subjects, and Caregivers

    Dec 1, 2023, 00:00

  • EE267 Cost-Effectiveness of a Web-Based Interactive Therapeutic Education Platform: Evidence From a Randomized Clinical Trial for Patients With End-Stage Renal Disease

    Dec 1, 2023, 00:00

  • HTA287 Impact of the 2020 Update of the French Guidelines for Economic Evaluation on the Economic Opinions Issued By the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • HSD15 Investigating the Impact of Early Versus Late Diagnosis in Fabry Disease on Healthcare Resource Utilization and Associated Costs in Greece

    Dec 1, 2023, 00:00

  • RWD8 Study of the Mental Health of Pharmacists During Wartime in Ukraine

    Dec 1, 2023, 00:00

  • EE76 End-of-Life Cost and Characteristics of Acute Myeloid Leukemia Decedents: A National Study From 2011-2020

    Dec 1, 2023, 00:00

  • PCR157 Assessment of Health State Utilities for Invasive Pneumococcal Disease, Pneumonia, and Acute Otitis Media in Young Children

    Dec 1, 2023, 00:00

  • HPR187 Is the Older Adult Subgroup of the Rare Disease Population Marginalized on Purpose? an Analysis of Equity Issues Encountered By the (OLDER) Rare Disease Population

    Dec 1, 2023, 00:00

  • HSD39 Treatment Pathway and Unmet Needs of Mantle Cell Lymphoma Patients: An Exploratory Study from Portugal

    Dec 1, 2023, 00:00

  • HTA118 Estimands in Health Technology Assessments: Methodological Considerations and Recommendations

    Dec 1, 2023, 00:00

  • EPH127 School Environment and Mental Health State in Brazilian Adolescents – Evaluating Public Policy Opportunities

    Dec 1, 2023, 00:00

  • HTA202 Guideline for Costing in Italian Economic Evaluations: A Proposal of the ISPOR Italy Rome Chapter

    Dec 1, 2023, 00:00

  • EE213 Presenting Expected Net Loss Curves to Better Communicate Decision Uncertainty in Cost Effectiveness Analysis

    Dec 1, 2023, 00:00

  • MT51 Does Current Reimbursement Drive the Adoption of Computer-Aided Applications to Increase the Adenoma Detection in Colonoscopies – a Provider-Based Impact Model for Germany, France, and Italy

    Dec 1, 2023, 00:00

  • CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data

    Dec 1, 2023, 00:00

  • MSR14 Unleashing the Potential of Artificial Intelligence in Genomic Biomarker Testing for Precision Oncology: A Scoping Review

    Dec 1, 2023, 00:00

  • EE158 Cost Effectiveness and Budget Impact of Patient Blood Management in a Turkish State Hospital

    Dec 1, 2023, 00:00

  • EE294 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccination Among 50 Years Old or Older in Austria

    Dec 1, 2023, 00:00

  • EE379 Economic Evaluation of Nubeqal for the Treatment of Adult Patients With Non-Metastatic Castration Resistant Prostate Cancer in the Mexican Context

    Dec 1, 2023, 00:00

  • EE251 The Impact of Cesarean Birth Complications on Maternal and Infant Health in the World and Turkiye

    Dec 1, 2023, 00:00

  • CO84 Characterization of Long-COVID Phenotypes and Associated Clinical Phenotypes in Administrative Claims Data

    Dec 1, 2023, 00:00

  • EE103 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Fulfil Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • EE587 A Systematic Scoping Review to Identify Challenges in the Economic Evaluation of Prognostic and Predictive Companion Diagnostics in Personalized Medicine: The Radioval Study

    Dec 1, 2023, 00:00

  • EPH202 Current Policy, Clinical and Economic Environment of Eye Care and Vision Health in Bulgaria

    Dec 1, 2023, 00:00

  • CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • HSD67 How Can a Digital Twin Help Achieve Technical Efficiency? an Application to the French Medical Genomics Pilot Sequencing Platform Auragen

    Dec 1, 2023, 00:00

  • HPR196 Loss of Exclusivity (LOE): Impact Analysis across Europe-5 and Select Nordic Countries

    Dec 1, 2023, 00:00

  • PCR210 Effectiveness of a Decision Aid for Parents/Caregivers of Children Needing Enteral Support

    Dec 1, 2023, 00:00

  • EE93 Real-World Cost-Effectiveness of Asfotase Alfa for Treatment of Patients with HPP in England

    Dec 1, 2023, 00:00

  • CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US

    Dec 1, 2023, 00:00

  • HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)

    Dec 1, 2023, 00:00

  • SA33 The Role of Artificial Intelligence in Decoding the Placebo Response - Implications for Clinical Research and Practice

    Dec 1, 2023, 00:00

  • CO62 Network Meta-Analysis (NMA) of Immuno-Oncology (IO) Treatments for First-Line (1L) Advanced or Metastatic Melanoma

    Dec 1, 2023, 00:00

  • HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK

    Dec 1, 2023, 00:00

  • HTA354 Cross Analysis of HAS Conclusions Amongst Products with an Economic Opinion Posted in 2022

    Dec 1, 2023, 00:00

  • HSD84 Financial Hardship from Neglected Tropical Diseases: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EPH123 A Machine Augmented Systematic Literature Review: Prevalence of Coinfections in COVID-19 Patients During Early and Late Pandemic Periods

    Dec 1, 2023, 00:00

  • EPH69 Disease Burden of Patients With Antibiotic-Resistant Bacteria (Extended-Spectrum Beta-Lactamase or Carbapenem-Resistant Enterobacteriaceae) in Korea

    Dec 1, 2023, 00:00

  • CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • HSD98 Patient Characteristics and Treatment Patterns in Patients with Advanced Psoriasis in Specialty Care Settings in Finland

    Dec 1, 2023, 00:00

  • PCR108 Pilot Testing the Hungarian Version of Online Elicitation of Personal Utility Functions Tool for Valuing EQ-5D-5L Health States

    Dec 1, 2023, 00:00

  • HTA119 Mapping a Path to Standardized Evidence Quality Tools Across EU HTA Agencies and NICE: Is EU Joint Clinical Assessment Guidance Falling Behind?

    Dec 1, 2023, 00:00

  • EE549 Systematic Review of the Cost Effectiveness of Newborn Screening for Severe Combined Immunodeficiency

    Dec 1, 2023, 00:00

  • HTA208 Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment: A Critical Appraisal

    Dec 1, 2023, 00:00

  • MSR34 Feasibility of Using Finnish Real-World Data to Build an External Control Arm for the Factor Xia Inhibitor Asundexian Pacific-AF Trial

    Dec 1, 2023, 00:00

  • MSR83 An Overview of “Multinma” Package: Multilevel Network Meta-Regression

    Dec 1, 2023, 00:00

  • MSR162 The Curse of Data Maturity in Observational Studies: Practical Advice from Protocol Development to Interpretation of Results

    Dec 1, 2023, 00:00

  • EE678 Time and Cost Savings from Adopting an Alternative Dosing Schedule with Pembrolizumab for Patients with Advanced Melanoma in Greece

    Dec 1, 2023, 00:00

  • EE632 Identification of Health State Utility Values for Health Economic Models: Empirical Testing of Alternative Search Methods

    Dec 1, 2023, 00:00

  • PCR167 Persistence and Adherence to Insulin Treatment in Chinese Patients with Type 2 Diabetes: A Real-World Study

    Dec 1, 2023, 00:00

  • CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00

  • CO12 5 Years of Real-World Data on the Use of Cladribine Tablets for the Treatments of Multiple Sclerosis in Portugal

    Dec 1, 2023, 00:00

  • Real-World Data Information Systems

    Dec 1, 2023, 00:00

  • PCR193 Health State Utilities Associated with X-Linked Retinitis Pigmentosa in the United Kingdom

    Dec 1, 2023, 00:00

  • HTA170 Assessing the Impact of the NICE Methods Review on Rare Diseases

    Dec 1, 2023, 00:00

  • HTA220 Incorporating Environmental Sustainability Considerations into National HTA Assessments: A Landscape Review

    Dec 1, 2023, 00:00

  • HTA262 Cost-Utility Analysis of Influenza Vaccination with a High Dose Quadrivalent Vaccine for the Brazilian Elderly Population in the Private Healthcare Sector

    Dec 1, 2023, 00:00

  • EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort

    Dec 1, 2023, 00:00

  • OP29 A Comparative Study of Patient Safety Culture Between 2013 and 2019 at a University Hospital in a Rural Area in Japan

    Dec 1, 2023, 00:00

  • HTA150 Health Technology Assessment of Domiciliary Invasive Ventilation for Adults With Spinal Cord Injuries

    Dec 1, 2023, 00:00

  • EE11 Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital

    Dec 1, 2023, 00:00

  • RWD171 Healthcare Resource Utilization and Cost of Renal Replacement Therapy in Brazil: A Five-Year Procedure-Level Analysis

    Dec 1, 2023, 00:00

  • HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis

    Dec 1, 2023, 00:00

  • EE206 Clinical and Economic Evaluation of Atezolizumab + Vemurafenib + Cobimetinib Combination in Treatment of Adult Patients with Metastatic Braf-Positive Melanoma

    Dec 1, 2023, 00:00

  • PCR100 Vascular Access Adverse Events: A Comprehensive Literature Review and Comparative Analysis

    Dec 1, 2023, 00:00

  • CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • RWD17 Methodology for the Development of a Data Collection Tool

    Dec 1, 2023, 00:00

  • MSR146 Proportional Hazards in Survival Analysis: A Review of the Variation in Determining and Presenting PH in NICE STAs

    Dec 1, 2023, 00:00

  • HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions

    Dec 1, 2023, 00:00

  • P44 Seeing it in the Flesch: Comparing Readability Between AI-Generated and Human-Written Plain-Language Abstracts

    Dec 1, 2023, 00:00

  • EE604 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Impact Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • HTA158 Exploring Efficiency of Living Systematic Literature Review (SLR) Tool for Submissions of Clinical Evidence to National Institute for Health and Care Excellence (NICE) by Combining Interventional and Real-World Evidence (RWE)

    Dec 1, 2023, 00:00

  • HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life

    Dec 1, 2023, 00:00

  • HTA178 Using Mixed-Methods Development-Focused HTA and Npv Calculations to Guide Further Investment and RD: A Case Study on Establishing the Value Proposition for Biosensor-Integrated Self-Reporting Arteriovenous Grafts

    Dec 1, 2023, 00:00

  • HPR44 Regional Inequalities in Access to Specialized Healthcare in the Brazilian Unified Health System

    Dec 1, 2023, 00:00

  • CO86 Comparing Factors Associated With First and Recurrent Psychiatric Hospitalizations in Adult Patients With Major Depressive Disorder Using Cox Proportional Hazard Model and Extensions

    Dec 1, 2023, 00:00

  • Study Approaches

    Dec 1, 2023, 00:00

  • MT43 Does Real-World Evidence Play a Role in Decision-Making by HTA Bodies for Medical Technologies?

    Dec 1, 2023, 00:00

  • CO29 Real-World Benefit of Ataluren Treatment in Milestones Not Related to Ambulatory Function in Nonsense Duchenne Muscular Dystrophy Versus Standard of Care

    Dec 1, 2023, 00:00

  • EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider?

    Dec 1, 2023, 00:00

  • HTA365 Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework

    Dec 1, 2023, 00:00

  • PCR182 Patient Preferences for Tumor-Agnostic Therapies: Qualitative Insights and Challenges

    Dec 1, 2023, 00:00

  • HTA177 The Safety and Effectiveness of Root Membrane Technique (Socket Shield Technique)

    Dec 1, 2023, 00:00

  • CO132 A Real-World Evidence Analysis of the Impact of Patient-Physician Sex Concordance on Cancer Treatment Practices and Outcomes

    Dec 1, 2023, 00:00

  • EE507 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer Unselected for DDR Mutations

    Dec 1, 2023, 00:00

  • PCR272 Qualitative Research to Explore Womens Experience of Vasomotor Symptoms and Evaluate the Suitability of Patient-Reported Outcomes

    Dec 1, 2023, 00:00

  • EE484 Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes

    Dec 1, 2023, 00:00

  • HTA186 Accelerating Access to Medical Technologies: An Overview of the NICE Early Value Assessment Pilot Project in the UK

    Dec 1, 2023, 00:00

  • EE523 Is Dismissing Intervention Development Costs a Fallacy? a Case Study of a Digital Health Intervention E-MAT

    Dec 1, 2023, 00:00

  • CO71 Faricimab Versus Standard of Care in Naive Neovascular Age-Related Macular Degeneration Patients: An Indirect Treatment Comparison Using Individual Level Data

    Dec 1, 2023, 00:00

  • CO173 Outcomes, Treatment Pattern, and Related Cost of Late-Stage Non-Small Cell Lung (NSCLC) Cancer in Taiwan

    Dec 1, 2023, 00:00

  • HPR69 Comparison of Price Trends for Medicines Pre- and Post-Early Access in Key Markets (France, UK, Australia)

    Dec 1, 2023, 00:00

  • EPH71 Tendencies in Hospital Burn Care for Children in Germany

    Dec 1, 2023, 00:00

  • CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • HTA140 The in Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Via the IMF

    Dec 1, 2023, 00:00

  • How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews

    Dec 1, 2023, 00:00

  • PCR125 Unmet Needs of People with Multiple Sclerosis: Findings for an Improvement of the Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • MSR53 Flexsurv Methods to Estimate Cure: An Exploration of Methods for Modelling Cure

    Dec 1, 2023, 00:00

  • EE48 Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Employment Changes for Early, Middle and Late-Stage People with Amyotrophic Lateral Sclerosis (pALS) in Italy: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • MSR111 Causal Inference and Statistical Considerations for Indirectly Comparing Time-to-Event Endpoints for Treatments with Different Starting Points for Outcome Assessment in Resectable NSCLC

    Dec 1, 2023, 00:00

  • MSR22 Standardized Contrasts Across Trials in Individual Patient Data Meta-Analysis With Time-to-Event Outcomes

    Dec 1, 2023, 00:00

  • HPR5 Implementing a Value-Based Payment Model for Patients with Osteoarthritis

    Dec 1, 2023, 00:00

  • PCR8 Perceived Barriers to HIV Prevention and Detection Among Adolescents and Young People, According to Civil Organization Leaders and Health Professionals in Chile

    Dec 1, 2023, 00:00

  • HTA351 A Targeted Review Exploring How English and German Health Technology Assessment Agencies Differ in Their Appraisal of Digital Health Apps

    Dec 1, 2023, 00:00

  • EE710 The Environmental, Healthcare, and Societal Impact of Asthma Pathway in the UK: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • HTA198 Comparisons of Economic Evaluation Guidelines Between Japan and Six Countries (England, France, Germany, Sweden, Canada and Australia)

    Dec 1, 2023, 00:00

  • OP22 Content Analysis of Drug Recall Announcements in Saudi Arabia: Between 2016 and 2022

    Dec 1, 2023, 00:00

  • EE411 Cost-per-Responder Analysis of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

    Dec 1, 2023, 00:00

  • EE630 The Economic Burden of Obesity in 4 Selected South-Eastern European Countries: Healthcare Resource Use and Costs Associated with Obesity-Related Comorbidities

    Dec 1, 2023, 00:00

  • P23 Evolving Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews (SLRs)

    Dec 1, 2023, 00:00

  • EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO)Adjuvant Treatment in Germany: An I-O Optimise Analysis

    Dec 1, 2023, 00:00

  • HPR134 Ethical Considerations in Pay-for-Performance Programs for Diabetes

    Dec 1, 2023, 00:00

  • PCR216 Patient-Driven Outcome Selection (PDOS): A Patient-Focused Approach for Selecting Outcomes Using Patient-Generated Data

    Dec 1, 2023, 00:00

  • EPH260 Rare Diseases and Kidney Stones: Are Stones in Amino Acid Transport Disorders Special?

    Dec 1, 2023, 00:00

  • EE345 Clinical and Economic Impact Analysis of Viscosupplementation With Hylan G-F 20 Versus Hyaluronic Acid for the Treatment of Knee Osteoarthrosis in Colombia

    Dec 1, 2023, 00:00

  • RWD77 Real-World Data Analysis Showing a Significant Improvement in Glycemic Control of People with T2D in Poland When Using a Blood Glucose Meter Connected to a Mobile Health App

    Dec 1, 2023, 00:00

  • HPR118 The Assessment of Alternative or Abbreviated Market Access Pathways for Pharmaceutical Reimbursement in 13 European Markets

    Dec 1, 2023, 00:00

  • PCR83 Fibrodysplasia Ossificans Progressiva (FOP): The Patient Experience

    Dec 1, 2023, 00:00

  • EE6 Expected Value of Perfect Implementation of Icosapent Ethyl (Vazkepa) in Sweden

    Dec 1, 2023, 00:00

  • HTA114 How Are Companion Diagnostics Evaluated and Reimbursed in Europe? Comparative Analysis of the EU-4 and UK

    Dec 1, 2023, 00:00

  • P40 Man Versus Machine: Can AI-Assisted Technology be Used to Support the Development of Economic Models?

    Dec 1, 2023, 00:00

  • EPH132 Epidemiology of Breast and Cervical Cancer in Women of the Colombian Caribbean Region During 2018-2021

    Dec 1, 2023, 00:00

  • P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • HTA56 Unequal Access of Innovative Drug Products Across Canada

    Dec 1, 2023, 00:00

  • EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial

    Dec 1, 2023, 00:00

  • RWD143 Beyond Accuracy: Automated De-Identification of Large Real-World Clinical Text Datasets

    Dec 1, 2023, 00:00

  • EE572 Budget Impact Analysis of the Introduction of Endo Arteriovenous Fistula System (WAVELINQ) for Hemodialysis Access Creation in Patients with End-Stage Kidney Disease

    Dec 1, 2023, 00:00

  • EE191 Projecting Costs of Care Burden of Depression Between 2023 and 2032 in Hong Kong: A Time-Inhomogeneous Cohort Markov Model Using Real-World Evidence

    Dec 1, 2023, 00:00

  • Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0

    Dec 1, 2023, 00:00

  • PT4 Patient-Reported Outcomes (PROs) in German AMNOG-Assessments: Impact of Increasing the Response Threshold to 15 %

    Dec 1, 2023, 00:00

  • CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • EE625 Time in Range As Alternative to HBA1C Change in the IQVIA Core Diabetes Model

    Dec 1, 2023, 00:00

  • HTA184 Review of HTA Evaluation for Gene Therapies and Their Future Implications in Europe

    Dec 1, 2023, 00:00

  • MSR52 Defining Severity Category Thresholds to Guide Psoriasis Symptoms and Impacts Measure Score Interpretation Using Pooled Data from Three Phase 3 Trials in Plaque Psoriasis

    Dec 1, 2023, 00:00

  • RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

    Dec 1, 2023, 00:00

  • PCR162 Talking with Teens: Techniques for Building Rapport with Adolescents in Virtual Qualitative Interviews

    Dec 1, 2023, 00:00

  • PCR254 Building a COA Strategy in Chronic Rhinosinusitis with or Without Nasal Polyps: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • CO146 Language Model-Based Approach for Extracting Comorbidities and Complications in Fabry Disease Clinical Notes

    Dec 1, 2023, 00:00

  • HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland

    Dec 1, 2023, 00:00

  • MSR55 How Different Are EQ-5D-Y Values in Asia? a Comparison Study of Four Jurisdictions

    Dec 1, 2023, 00:00

  • EE440 Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Indian Adults Aged ≥60 Years

    Dec 1, 2023, 00:00

  • PCR54 Knowledge, Attitudes and Practices of Patients Towards Generics in Greece

    Dec 1, 2023, 00:00

  • PCR58 Social Media Research to Understand Reported Efficacy of GLP-1 RAs for Weight Loss

    Dec 1, 2023, 00:00

  • MSR8 Nesting a Decision Tree into a Markov Model Structure: An Alternative Way of Tracking Movement in a Diagnostic Model

    Dec 1, 2023, 00:00

  • MSR73 Methods for Incorporating External Eviden A Comparison of Their Impact on Extrapolations and Uncertainty Estimates Using a Melanoma Case-Study

    Dec 1, 2023, 00:00

  • MSR37 Validation of the Ibadan Knee/Hip Osteoarthritis Outcome Measure (IKHOAM) Among Patients With Knee Osteoarthritis

    Dec 1, 2023, 00:00

  • EE159 Cost-Effectiveness Analysis of an Adjusted Polygenic Risk Score in Cardiovascular Disease Prevention

    Dec 1, 2023, 00:00

  • HPR86 Reducing Inequity: Does the New EU Pharmaceutical Legislation Address Challenges to Pharmaceutical Access in Central and Eastern Europe?

    Dec 1, 2023, 00:00

  • EPH14 Burden of Respiratory Syncytial Virus Infection in Germany: A Systematic Review

    Dec 1, 2023, 00:00

  • HPR202 The Digital Transformation: How Could Artificial Intelligence (AI) Re-Shape Drug Launch?

    Dec 1, 2023, 00:00

  • EE102 Economic Burden of Short-Acting Beta-2 Agonist Overuse Among Asthma Patients in Turkiye: A Cost Analysis with Respect to Updated Recommendations of the Global Initiative for Asthma

    Dec 1, 2023, 00:00

  • EPH87 Real-World Evidence Study on Hemophilia B Treatment with Factor IX and Corresponding Treatment Costs in Finland

    Dec 1, 2023, 00:00

  • HTA73 Health Technology Assessment (HTA) Timelines Analysis in the Post-COVID Era: Comparison of HTA Process Duration in the First Half (H1) of 2023 to H1 2022

    Dec 1, 2023, 00:00

  • HPR107 Bilateral Price Comparison of 50 Particularly Cost-Intensive Drugs – What Is the Impact of Different Reimbursement Rules?

    Dec 1, 2023, 00:00

  • EE653 A Health Economic Model to Assess the Effects of Introducing Home Polysomnography for the Diagnosis of Sleep Apnea in Germany

    Dec 1, 2023, 00:00

  • EE420 Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease (CKD) Management in the UK

    Dec 1, 2023, 00:00

  • HSD87 Physician Reported Reasons for Cidp Treatment Choice across 5 European Countries: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC)

    Dec 1, 2023, 00:00

  • HTA163 Setting Treatment Selection Criteria for Breast Cancer From a Clinician Perspective: Is It a Matter of Cost?

    Dec 1, 2023, 00:00

  • PCR118 Cross-Sectional Measurement Properties of the Physical Distancing Scale – COVID-19 (PDS-C19) Self- and Observer-Reported Measure of Physical Distancing Behaviors to Avoid COVID-19 in Adults, Children, and Caregivers

    Dec 1, 2023, 00:00

  • EE448 Exploring Non-Patient Utilities Using Time Trade-Off Exercises in the UK General Population

    Dec 1, 2023, 00:00

  • HTA9 Success Rate of Cancer Drugs Fund Reappraisals

    Dec 1, 2023, 00:00

  • SA78 Active Participation of Children in Health Research: Methods, Experience and Ethical Aspects

    Dec 1, 2023, 00:00

  • P38 Forecasting Emergency Department Waiting Times Using Deep Neural Networks

    Dec 1, 2023, 00:00

  • EE280 The Lean Assessment Process (LAP) Methodology: An Iterative and Multi-Disciplinary Method for Identifying Clinical Needs, Assessing Technology Acceptance, a Precursor for Early Economic Evaluation and Adoption Strategies

    Dec 1, 2023, 00:00

  • EE724 Inside CKD: Projecting the Population Level Economic Burden of Chronic Kidney Disease According to Urine Albumin-to-Creatinine Ratio (uACR) Categories

    Dec 1, 2023, 00:00

  • EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy

    Dec 1, 2023, 00:00

  • HSD44 Healthcare Resource Utilization of Severe Eosinophilic Asthma Patients Treated With Benralizumab in Real-Life: Results From the Portuguese BETREAT Study

    Dec 1, 2023, 00:00

  • EE490 Analysis of Access and Avalibility of Low Molecular Heparins for the Treatment of COVID-19 during Wartime in Ukraine

    Dec 1, 2023, 00:00

  • HTA71 Bridging the Gap: Exploring the PICO Vs Estimand Frameworks in EU Health Technology Assessment (HTA)

    Dec 1, 2023, 00:00

  • MSR80 AI-Enabled Risk of Bias Assessment of RCTs in Systematic Reviews: A Case Study

    Dec 1, 2023, 00:00

  • CO87 Lifetime Cumulative Risk of Bone Fracture in Chinese Male Patients with Osteoporosis: A Model Simulation Study

    Dec 1, 2023, 00:00

  • HSD22 Vaccine Preparation Time, Cost, and Preference Comparison Between Pre-Filled Syringe Formulations and Vaccines That Require Reconstitution: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • Reflecting Parameter Uncertainty in Addition to Variability in Constrained Healthcare Resource Discrete Event Simulations: Worth Going the Extra Mile or a Road to Nowhere?

    Dec 1, 2023, 00:00

  • EE147 "I'll Live Less, You'll Live Better, Let's Make It Count": A Qualitative Exploration of Drivers Barriers for Sacrificing Remaining Life Expectancy to Restore Relatives to Full Health in Time Trade Off Exercises

    Dec 1, 2023, 00:00

  • EPH205 Inside CKD: Predicting the Clinical and Economic Burden of Chronic Kidney Disease in Belgium

    Dec 1, 2023, 00:00

  • HSD80 Employees Satisfaction Working at Arta General Hospital of Greece

    Dec 1, 2023, 00:00

  • HTA104 Data on Patient-Reported Outcomes Is Not a Prerequisite for Achieving an Additional Benefit in German Early Benefit Assessment of New Medicinal Products Approved for Dermatological Diseases

    Dec 1, 2023, 00:00

  • SA58 Approaches to Examine Treatment Adherence and Persistence Using German Claims Data: An Exemplary Analysis Using Oral Therapies for Prostate Cancer

    Dec 1, 2023, 00:00

  • EPH176 Comorbidities Among Individuals at Risk to Develop Severe Form of COVID-19 in Case of Sars-Cov-2 Infection

    Dec 1, 2023, 00:00

  • EPH232 The Disease Burden and Healthcare Resource Utilization of Gram-Negative Multi-Drug Resistant Bacteria

    Dec 1, 2023, 00:00

  • OP7 Coverage and Equity of a Patient Support Program for Diabetes During the Pandemic Period in a Middle-Income Country

    Dec 1, 2023, 00:00

  • HPR100 Orphan Drugs in Algeria and Six Other Countries: A Cross Comparison Study

    Dec 1, 2023, 00:00

  • PT23 Is It Possible to Estimate the Welfare Economic Loss to Society of Not Having Value-Based Differential Pricing for Multi-Indication Pharmaceuticals: An Empirical Analysis in Denmark, Norway, and Sweden

    Dec 1, 2023, 00:00

  • EE629 The Obesity Burden and Impact of Weight Loss on Saudi Public Payers Using Value of Weight Loss Simulation Model

    Dec 1, 2023, 00:00

  • EPH125 A Systematic Literature Review and Meta-Analysis on the Disease Burden of Chikungunya

    Dec 1, 2023, 00:00

  • RWD7 Graphical Representation of Real-World Data for Analysing Infection Outbreaks Within a Tertiary Hospital Setting: A Data-Driven Approach

    Dec 1, 2023, 00:00

  • MT33 Cost-Effectiveness Analysis of Watchman FLX Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation

    Dec 1, 2023, 00:00

  • EE538 Hospital Budget Impact of a Lung Suite Navigation Platform to Diagnose and Treat Lung Cancer Patients

    Dec 1, 2023, 00:00

  • EPH196 Prevalence of GI Comorbidities by Age Group Among Patients With Rett Syndrome: An Analysis of Coded EHR and Pharmacy Data and Clinical Notes

    Dec 1, 2023, 00:00

  • EPH93 Progression From Cutaneous to Systemic Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE377 Budget Impact Analysis of Implementing a Breast Cancer Screening Program in Bulgaria

    Dec 1, 2023, 00:00

  • HPR112 International Market Access Strategies for Artificial Intelligence-Based Medical Devices: Can We Standardized the Process to Faster Patient Access?

    Dec 1, 2023, 00:00

  • EPH161 Epidemiology Landscape and Impact of Obesity: Multi-Country Results from the Impact-O Study

    Dec 1, 2023, 00:00

  • EE626 Budget Impact Analysis (BIA) of Adopting Real-Time Continuous Glucose Monitoring (rt-CGM) vs Intermittent-Scanning Continuous Glucose Monitoring (is-CGM) in Patients With Type 1 Diabetes on Insulin Therapy (PWT1D) in Italy

    Dec 1, 2023, 00:00

  • EE651 Incremental Cost per Remission in Patients With Rheumatoid Arthritis Who Had Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Colombia

    Dec 1, 2023, 00:00

  • HSD50 Infantile Vaccination Coverage in Brazil From 2016-2022 – Effects of Pandemic Period in Non-COVID-19 Vaccination

    Dec 1, 2023, 00:00

  • EE254 Budget Impact of Telemonitoring (TM)-Enabled Care of Obstructive Sleep Apnea Hypoanpnea Syndrome (OSAH) in the UK

    Dec 1, 2023, 00:00

  • HPR37 Squaring the Circle? Leveraging Early Access / Compassionate Use Pathways to Provide Market-Specific Real-World Evidence Before Launch

    Dec 1, 2023, 00:00

  • EE340 Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore.

    Dec 1, 2023, 00:00

  • CO68 Gastrointestinal Manifestations and Incontinence Products in the Real World Among Patients with Rett Syndrome in the United States

    Dec 1, 2023, 00:00

  • RWD120 Analysis of the Impact of National Medical Insurance Negotiation Policy on the Accessibility of Anti-Cancer Drugs in a City in China

    Dec 1, 2023, 00:00

  • PCR214 Patient Voice in Pharmaceutical Company: The Case of Patient Committee in Brazil

    Dec 1, 2023, 00:00

  • RWD47 Non-Motor Symptoms Burden and Quality of Life in Patients with Parkinson’s Disease (PD)

    Dec 1, 2023, 00:00

  • HTA83 Economic Evaluations in Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Challenges for Health Technology Assessment (HTA) Submissions

    Dec 1, 2023, 00:00

  • HTA352 The Significance of Literature Reviews in the Process of Decision-Making by the Haute Autorité De Santé

    Dec 1, 2023, 00:00

  • P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • RWD170 Investigating the Association between Pain Burden and Multimorbidity Among United States Adults with Pain

    Dec 1, 2023, 00:00

  • RWD36 Immunoglobulin Use in France 2015 to 2022–Real-World Data From the French Claims Database

    Dec 1, 2023, 00:00

  • MT18 Endovascular Management of Iliac and Aorto-Iliac Aneurysms and Impact on Morbidity/Mortality in Fran A French National Insurance Claims Database Analysis (SNDS)

    Dec 1, 2023, 00:00

  • PT22 Exploring Reimbursement Disparities: A Comparative Study of Pharmaceutical Access in Hong Kong and Mainland China

    Dec 1, 2023, 00:00

  • PCR201 Estimating the Respiratory Syncytial Virus (RSV) Health Utility Values for Older Adults and Their Caregivers in the Japanese Population: A Time Trade-Off (TTO) Study

    Dec 1, 2023, 00:00

  • MSR124 Improving the Efficiency of Using the Guyot Algorithm to Construct Pseudo Individual Patient Data From Kaplan-Meier Survival Curves: Standardized Guidance and Data Preparation

    Dec 1, 2023, 00:00

  • EE182 Costs and Health Impact of Wastewater Surveillance to Guide Respiratory Syncytial Virus Prophylaxis in Canada, Compared to Clinical Surveillance

    Dec 1, 2023, 00:00

  • MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials

    Dec 1, 2023, 00:00

  • EE138 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Singaporean Adults Aged ≥18 Years

    Dec 1, 2023, 00:00

  • HTA243 Guidelines for Incorporating the Societal Perspective and Wider Societal Benefits in Health Technology Assessment

    Dec 1, 2023, 00:00

  • PCR41 The Impact of Moderate to Severe Chronic Hand Eczema and the Effect of Improved Clinical Symptoms on Work Productivity Loss: Data from the DELTA 1 and DELTA 2 Phase 3 Trials

    Dec 1, 2023, 00:00

  • RWD44 Utilization of Short-Term and Long-Term Disability, and Workers' Compensation in Employees with Major Depressive Disorder Compared with Employed Controls

    Dec 1, 2023, 00:00

  • RWD98 Health Care Resource Use and Costs of Hemophilia A in France

    Dec 1, 2023, 00:00

  • PT16 Impact of Data Maturity on the Estimation of the within-Trial Hazard Function: An Example from Metastatic Castration Resistant Prostate Cancer

    Dec 1, 2023, 00:00

  • CO100 Regular Laboratory Checks for Ileostomy Patients After Surgery Are Not Performed Comprehensively, but Could Result in Better Health Outcomes

    Dec 1, 2023, 00:00

  • RWD108 Real-World Data and Real-World Evidence Terminology Harmonization: Evidence Gaps and Future Steps

    Dec 1, 2023, 00:00

  • EE500 An Overview of Systematic Literature Review of Economic Evaluation of Treatment on Patients With Alzheimer's Disease and Related Dementia

    Dec 1, 2023, 00:00

  • HTA193 Benefits Not Captured in the Quality-Adjusted Life Year Calculation: What Role Do They Play in the National Institute for Health and Care Excellence's Updated Decision-Making Process?

    Dec 1, 2023, 00:00

  • EE270 Predicting Persistent Severe Acute Kidney Injury (AKI) Using the Urinary C-C Motif Chemokine Ligand 14 Biomarker (CCL14). Cost-Utility Analysis in Spain and the UK

    Dec 1, 2023, 00:00

  • HSD123 Environmental Impact of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in the Netherlands

    Dec 1, 2023, 00:00

  • CO51 Safety Profile of Approved Alzheimer's Medication By USFDA

    Dec 1, 2023, 00:00

  • PCR263 Design of a Patient-Informed Chronic Kidney Disease (CKD) Experience Interview Guide: Learnings From DISCOVER CKD

    Dec 1, 2023, 00:00

  • EPH241 Labor-Market Affiliation Among Danish Migraine Patients Discontinuing Triptan Treatment—A Register-Based Study

    Dec 1, 2023, 00:00

  • EPH190 Clinical Characteristics and Treatment Patterns of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Mexico

    Dec 1, 2023, 00:00

  • EE562 What Is More Valuable Than Optimal Resource Use? The Development of Interactive Tool Visualizing the Costs and Time Consumption Related to Diabetic Macular Edema’s Intravitreal Treatments in Finland

    Dec 1, 2023, 00:00

  • EE66 Cost Effectiveness Analysis of Pembrolizumab as First-Line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer in Greece

    Dec 1, 2023, 00:00

  • EE563 Cost-Effectiveness of the PPARγ Modulator N-Acetyl-Ged-0507-34-Levo (NAC-GED 5%) Versus Benzoyl Peroxide-Adapalene for Moderate to Severe Acne

    Dec 1, 2023, 00:00

  • HPR133 Analysis of Information Content on the Web Services About Antihypertensive Medicines in Ukraine

    Dec 1, 2023, 00:00

  • HSD38 From Unpersonalized to Personalized Breast Follow-up in Clinical Practice in the Netherlands: Will Artificial Intelligence Make a Difference?

    Dec 1, 2023, 00:00

  • RWD5 Body Fatness Associations with Cancer: Retrospective Cohort Study from a Brazilian Health Management Organization (RWE)

    Dec 1, 2023, 00:00

  • RWD116 The Economic Burden of Moderate to Severe Rheumatoid Arthritis (RA) in Spain: Interim 6-Month Results

    Dec 1, 2023, 00:00

  • EE551 Study of Costs of Hereditary Angioedema in Routine Clinical Practi Economic Impact of the Disease Burden in Spain

    Dec 1, 2023, 00:00

  • MT61 Differences and Similarities of Health Economic Evaluation for Medical Technologies By HTA Bodies

    Dec 1, 2023, 00:00

  • HSD105 Pharmacists' Intervention in Access to Therapeutical Innovation in Portuguese Hospitals

    Dec 1, 2023, 00:00

  • EE325 Healthcare Resource Use and Costs Associated with Obesity and Obesity-Related Complications in Saudi Arabia

    Dec 1, 2023, 00:00

  • EE413 Economic and Humanistic Burden of Chronic Spontaneous Urticaria: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MT6 Companion Diagnostics’ Launch and Market Access Landscape: Who Are the Trend Setters and Late Adopters?

    Dec 1, 2023, 00:00

  • HPR165 Financial-Based Managed Entry Agreements for Drugs in Romania: From Simple to Complex

    Dec 1, 2023, 00:00

  • PT31 A Time Series Analysis of Immune Checkpoint Inhibitors Use in Italian Population: 2017-2022

    Dec 1, 2023, 00:00

  • EE566 Systematic Literature Review for Utility Data in Haemophilia

    Dec 1, 2023, 00:00

  • CO184 Exploring the Relationship Between Surrogate and Long-Term Outcomes in Lysosomal Storage Diseases: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • PCR246 Measuring Treatment Preferences for Patients with Pulmonary Arterial Hypertension (PAH); A Discrete Choice Analysis to Identify Scale Heterogeneity

    Dec 1, 2023, 00:00

  • PCR37 The Impact of Leber’s Heredity Optic Neuropathy (LHON) on Quality of Life (QoL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • HTA181 How Can Health Technology Assessment Help in Addressing Drug Repurposing Challenges? A Conceptual Framework

    Dec 1, 2023, 00:00

  • PCR271 Employing Episodic Future Thinking to Reduce the Distortion of Time Preference in Time Trade-Off Valuation

    Dec 1, 2023, 00:00

  • HTA247 Focus on Two Years of Economic Opinions on Orphan Drug: What Are the Specific Features?

    Dec 1, 2023, 00:00

  • MT10 Clinical and Economic Impact of Point-of-Care (POC) Molecular Testing in Patients Presenting With Viral Respiratory Symptoms: A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • PCR179 The Socio-Economic and Health-Related Quality of Life Impact of Myasthenia Gravis (MG) in Greece

    Dec 1, 2023, 00:00

  • EE113 The Use of Ferric Carboxymaltose for Pregnant and Postpartum Women in Brazil: Estimation of Target Poputation and Budget Impact Analysis from the Public Health Care System Perspective

    Dec 1, 2023, 00:00

  • HSD111 Real-World Treatment Patterns of Ankylosing Spondylitis

    Dec 1, 2023, 00:00

  • RWD174 Using Real-World Evidence to Quantify Hospital Costs of Subcutaneous Implantable Cardioverter-Defibrillator Infections in the US

    Dec 1, 2023, 00:00

  • EE184 Lessons Learned from Model-Based Economic Evaluations of COVID-19 Treatments Under Pandemic Circumstances: Results from a Systematic Review

    Dec 1, 2023, 00:00

  • HTA245 UK Mechanisms to Address Rare Disease Challenges: Does the UK Go Far Enough?

    Dec 1, 2023, 00:00

  • HTA295 Insights From Economic Evaluations in Emerging Infection Diseases in Fran Focus on COVID-19

    Dec 1, 2023, 00:00

  • PCR219 Hungarian Population Norms for the 15D Generic Preference-Accompanied Health Status Measure

    Dec 1, 2023, 00:00

  • EE605 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2022

    Dec 1, 2023, 00:00

  • HTA171 The Use of Qualitative Methods in the NICE HST Deliberative Process

    Dec 1, 2023, 00:00

  • CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

    Dec 1, 2023, 00:00

  • EE246 Is It Possible to Reduce the Costs of Care for Pediatric Patients With Hemophilia A and Inhibitors in Trinidad Tobago?

    Dec 1, 2023, 00:00

  • HTA86 Factors Affecting Time to Reimbursement of Novel Anticancer Drugs in Ireland

    Dec 1, 2023, 00:00

  • EE449 Uncertainty Around HRQoL Values Is Under-Reported: Are We Misleading Decision Makers?

    Dec 1, 2023, 00:00

  • CO137 Health Outcomes of ALK-Inhibitors in Non-Small Cell Lung Cancer in Real Clinical Practice

    Dec 1, 2023, 00:00

  • SA63 Planning Phase 3 Clinical Trials More Efficiently Using an Evidence-Mapping Approach

    Dec 1, 2023, 00:00

  • HPR15 Review and Evaluation of Health Equity Considerations in Health Technology Assessments in Cystic Fibrosis

    Dec 1, 2023, 00:00

  • EE432 Propel® Technology – A Budget Impact Analysis in the Italian Context

    Dec 1, 2023, 00:00

  • EE408 Pharmacoeconomic Analysis of Abrocitinib in Patients with Severe Atopic Dermatitis Versus Systemic Treatments in Spain

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22 (current)
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • »